Published in Pancreas on March 01, 2009
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Proteomic mucin profiling for the identification of cystic precursors of pancreatic cancer. J Natl Cancer Inst (2014) 1.69
Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol Cell Proteomics (2011) 1.19
MUC5B Is the predominant mucin glycoprotein in chronic otitis media fluid. Pediatr Res (2010) 1.11
Epidemiology, diagnosis, and management of cystic lesions of the pancreas. Gastroenterol Res Pract (2011) 0.98
Mass spectrometry-based proteomics of endoscopically collected pancreatic fluid in chronic pancreatitis research. Proteomics Clin Appl (2011) 0.96
PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Cancer (2012) 0.95
Inhibition of AMPK and Krebs cycle gene expression drives metabolic remodeling of Pten-deficient preneoplastic thyroid cells. Cancer Res (2013) 0.95
Optimized sample preparation of endoscopic collected pancreatic fluid for SDS-PAGE analysis. Electrophoresis (2010) 0.95
Glycomic and proteomic profiling of pancreatic cyst fluids identifies hyperfucosylated lactosamines on the N-linked glycans of overexpressed glycoproteins. Mol Cell Proteomics (2012) 0.94
Proteomic analysis (GeLC-MS/MS) of ePFT-collected pancreatic fluid in chronic pancreatitis. J Proteome Res (2012) 0.94
A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma. Genes Cancer (2010) 0.93
Assessment of two immunodepletion methods: off-target effects and variations in immunodepletion efficiency may confound plasma proteomics. J Proteome Res (2012) 0.93
Metabolomic-derived novel cyst fluid biomarkers for pancreatic cysts: glucose and kynurenine. Gastrointest Endosc (2013) 0.90
Comparison of surgical and endoscopic sample collection for pancreatic cyst fluid biomarker identification. J Proteome Res (2012) 0.85
Analysis of the plasma proteome in COPD: Novel low abundance proteins reflect the severity of lung remodeling. COPD (2013) 0.84
Isobaric labeling and data normalization without requiring protein quantitation. J Biomol Tech (2012) 0.84
Difference gel electrophoresis identifies differentially expressed proteins in endoscopically collected pancreatic fluid. Electrophoresis (2011) 0.83
Potential prognostic biomarkers of pancreatic cancer. Pancreas (2014) 0.83
Pancreatic cystic lesions: How endoscopic ultrasound morphology and endoscopic ultrasound fine needle aspiration help unlock the diagnostic puzzle. World J Gastrointest Endosc (2012) 0.82
Characterization of glycoproteins in pancreatic cyst fluid using a high-performance multiple lectin affinity chromatography platform. J Proteome Res (2013) 0.81
The use of protein-based biomarkers for the diagnosis of cystic tumors of the pancreas. Int J Proteomics (2011) 0.80
Cyst Fluid Glucose is Rapidly Feasible and Accurate in Diagnosing Mucinous Pancreatic Cysts. Am J Gastroenterol (2015) 0.79
Systematic Review of Pancreatic Cyst Fluid Biomarkers: The Path Forward. Clin Transl Gastroenterol (2015) 0.79
Proteomics analysis of bodily fluids in pancreatic cancer. Proteomics (2015) 0.78
Analysis of endoscopic pancreatic function test (ePFT)-collected pancreatic fluid proteins precipitated via ultracentrifugation. JOP (2013) 0.77
Differentiation of mucinous from non-mucinous pancreatic cyst fluid using dual-stained, 1 dimensional polyacrylamide gel electrophoresis. Clin Proteomics (2014) 0.75
Endoscopic ultrasound in the diagnosis of pancreatic intraductal papillary mucinous neoplasms. World J Gastroenterol (2014) 0.75
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Clustal W and Clustal X version 2.0. Bioinformatics (2007) 126.47
Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics (2005) 10.67
Specific carcinoembryonic antigens of the human digestive system. J Exp Med (1965) 9.96
Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics (2005) 8.92
Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics (2007) 6.96
Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology (2004) 6.75
Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci U S A (2007) 4.80
Cystic neoplasms of the pancreas. N Engl J Med (2004) 3.89
Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol (2003) 3.62
Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst (2005) 3.31
Pancreatic anastomotic leak after pancreaticoduodenectomy: incidence, significance, and management. Am J Surg (1994) 2.69
A review of the S100 proteins in cancer. Eur J Surg Oncol (2007) 2.64
Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res (1999) 2.25
CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol (2006) 2.13
Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms? Ann Surg (2000) 2.05
Cyst fluid analysis in the differential diagnosis of pancreatic cysts. A comparison of pseudocysts, serous cystadenomas, mucinous cystic neoplasms, and mucinous cystadenocarcinoma. Ann Surg (1993) 1.97
Pancreatic cancer. Curr Probl Cancer (2002) 1.92
Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta (2006) 1.65
Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas. Am J Surg Pathol (1999) 1.59
Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J Proteome Res (2005) 1.45
The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin Cancer Res (2005) 1.33
Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol (2007) 1.32
ASGE guideline: complications of EUS. Gastrointest Endosc (2005) 1.32
A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery. Mol Cell Proteomics (2007) 1.24
Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics (2003) 1.14
Progress on molecular markers of pancreatic cancer. Curr Opin Gastroenterol (2007) 1.11
Partitioning large-sample microarray-based gene expression profiles using principal components analysis. Comput Methods Programs Biomed (2003) 1.09
Clinicopathologic view of intraductal papillary-mucinous tumor of the pancreas. Hepatogastroenterology (1999) 1.09
Cystic and pseudocystic diseases of the pancreas. Curr Probl Surg (1994) 1.07
Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue. Proteomics (2004) 1.06
A quantitative results-driven approach to analyzing multisite protein phosphorylation: the phosphate-dependent phosphorylation profile of the transcription factor Pho4. Mol Cell Proteomics (2006) 1.05
S100A8 and S100A9 in inflammatory diseases. Lancet (2001) 1.05
S100A11, a putative tumor suppressor gene, is overexpressed in pancreatic carcinogenesis. Clin Cancer Res (2006) 0.99
Inciting inflammation: the RAGE about tumor promotion. J Exp Med (2008) 0.99
Proteomics of pancreatic cancer. Pancreas (2008) 0.95
Searchable high-resolution 2D gel proteome of the human colon crypt. J Proteome Res (2007) 0.92
The level of carcinoembryonic antigen and the presence of mucin as predictors of cystic pancreatic mucinous neoplasia. Pancreas (2007) 0.91
Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound-guided fine-needle aspiration specimens of the pancreas. Int J Cancer (2007) 0.91
Diagnostic value of CA 72-4 and carcinoembryonic antigen determination in the fluid of pancreatic cystic lesions. Eur J Gastroenterol Hepatol (1998) 0.91
Analyzing alkaline proteins in human colon crypt proteome. J Proteome Res (2004) 0.90
[Diagnosis of cystadenomas and cystadenocarcinomas of the pancreas. Study of 35 cases]. Gastroenterol Clin Biol (1995) 0.84
Detection of gastric mucins (M1 antigens) in cyst fluid for the diagnosis of cystic lesions of the pancreas. Int J Cancer (1997) 0.82
[Pancreatic cancer]. Praxis (Bern 1994) (2006) 0.78
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol (2008) 4.79
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Quality indicators for colonoscopy. Gastrointest Endosc (2014) 4.17
Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol (2012) 3.98
Global gene expression profiling of circulating tumor cells. Cancer Res (2005) 3.41
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol (2007) 3.37
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Multiple phytochrome-interacting bHLH transcription factors repress premature seedling photomorphogenesis in darkness. Curr Biol (2008) 3.23
Wireless capsule endoscopy. Gastrointest Endosc (2013) 3.21
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Genetic and environmental risk assessment and colorectal cancer screening in an average-risk population: a randomized trial. Ann Intern Med (2014) 2.89
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol (2009) 2.88
Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol (2008) 2.81
Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol (2006) 2.72
Genome-wide analyses of avian sarcoma virus integration sites. J Virol (2004) 2.68
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol (2011) 2.57
Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys (2011) 2.54
Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med (2012) 2.47
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol (2002) 2.41
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
Centralization of cancer surgery: implications for patient access to optimal care. J Clin Oncol (2009) 2.40
Tissue adhesives: cyanoacrylate glue and fibrin sealant. Gastrointest Endosc (2013) 2.38
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol (2011) 2.38
Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos). Gastrointest Endosc (2011) 2.30
Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol (2004) 2.27
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol (2008) 2.15
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol (2006) 2.10
Quality indicators for colonoscopy. Am J Gastroenterol (2014) 2.06
Thyroid carcinoma. J Natl Compr Canc Netw (2010) 2.02
Acute gastrointestinal bleeding. Ann Intern Med (2013) 2.01
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2012) 1.97
Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol (2010) 1.93
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer (2008) 1.89
The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist (2007) 1.89
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol (2011) 1.86
The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer (2010) 1.84
Correlates of colorectal cancer screening compliance and stage of adoption among siblings of individuals with early onset colorectal cancer. Health Psychol (2002) 1.84
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol (2008) 1.80
Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res (Phila) (2010) 1.80
Management of bleeding GI tumors. Gastrointest Endosc (2010) 1.79
Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res (2002) 1.78
RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res (2007) 1.76
Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer (2006) 1.72
Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Int J Radiat Oncol Biol Phys (2007) 1.71
Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem (2002) 1.70
Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. J Clin Oncol (2010) 1.69
Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. PLoS One (2009) 1.68
Endoscopic closure devices. Gastrointest Endosc (2012) 1.66
Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res (2004) 1.66
The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. Cancer (2003) 1.65
Validation of the S-LANSS in the community setting. Pain (2007) 1.65
Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer. Clin Cancer Res (2011) 1.59
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res (2010) 1.59
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology (2012) 1.58
Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biol Ther (2004) 1.58
Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci U S A (2003) 1.58
The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg (2004) 1.57
Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res (2003) 1.56
Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care. J Clin Oncol (2003) 1.54
Laparoscopic pancreatoduodenectomy: a review of 285 published cases. Ann Surg Oncol (2011) 1.54
Nanocytology of rectal colonocytes to assess risk of colon cancer based on field cancerization. Cancer Res (2012) 1.53
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer (2007) 1.52
Pancreatic adenocarcinoma. J Natl Compr Canc Netw (2010) 1.52
Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction. J Clin Oncol (2002) 1.49
The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. J Oncol Pract (2013) 1.48
Telomerase is frequently activated in tumors with microsatellite instability. Cancer Biol Ther (2004) 1.47
Double balloon enteroscopy detects small bowel mass lesions missed by capsule endoscopy. Dig Dis Sci (2008) 1.46
Hematoma risk after needle electromyography. Muscle Nerve (2012) 1.46
Double balloon enteroscopy: effective and minimally invasive method for removal of retained video capsules. Dig Endosc (2014) 1.43
The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci U S A (2003) 1.41
Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation. Ann Fam Med (2009) 1.41
Grading follicular lymphoma. The Achilles heel of diagnosis by cytology. Acta Cytol (2004) 1.40
Nonneoplastic celiac axis occlusion in patients undergoing pancreaticoduodenectomy. Am J Surg (2007) 1.39
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res (2005) 1.39
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas (2008) 1.38